Annals of the American Thoracic Society
-
Multicenter Study Clinical Trial
Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.
In cystic fibrosis (CF), pulmonary exacerbations present an opportunity to define the effect of antibiotic therapy on systemic measures of inflammation. ⋯ Circulating inflammatory proteins demonstrate and predict a response to treatment of CF pulmonary exacerbations. A systemic biomarker panel could speed up drug discovery, leading to a quicker, more efficient drug development process for the CF community.
-
Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012.
Pulmonary nontuberculous mycobacteria (NTM) disease is a chronic, nonreportable illness, making it difficult to monitor. Although recent studies suggest an increasing prevalence of NTM disease in the United States, the incidence and temporal trends are unknown. ⋯ This is the first population-based estimate of pulmonary NTM disease incidence in a region within the United States. In Oregon, disease incidence rose slightly during 2007 to 2012, and although more common in female individuals overall, disease was more common among male individuals less than 60 years of age.
-
Volatile organic compounds present in the exhaled breath have shown promise as biomarkers of lung cancer. Advances in colorimetric sensor array technology, breath collection methods, and clinical phenotyping may lead to the development of a more accurate breath biomarker. ⋯ The colorimetric sensor array signature of exhaled breath volatile organic compounds was capable of distinguishing patients with lung cancer from clinically relevant control subjects in a discovery level trial. The incorporation of clinical phenotypes into the further development of this biomarker may optimize its accuracy.